<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent evidence indicates that toll-like receptor (TLR) 2 and 4 are involved in the pathogenesis of <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> (<z:chebi fb="20" ids="15767">DCM</z:chebi>), but the exact mechanisms of their actions have not been elucidated </plain></SENT>
<SENT sid="1" pm="."><plain>We explored the therapeutic potential of blocking TLRs in mice with established <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0001638'>Cardiomyopathy</z:hpo> was generated by a single intraperitoneal injection of <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (10 mg/kg) </plain></SENT>
<SENT sid="3" pm="."><plain>Two weeks later, the mice were treated with TLR2 or TLR4 neutralizing antibody </plain></SENT>
<SENT sid="4" pm="."><plain>Blocking TLR2, but not TLR4, activity not only reduced mortality, but also attenuated <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>-induced cardiac dysfunction by 20% and inhibited <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>To determine the differential effects of blocking TLR2 and TLR4 in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, mice were injected with <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (3.5 mg/kg) once a week for 8 weeks, followed by treatment with TLR2 or TLR4 neutralizing antibody for 40 days </plain></SENT>
<SENT sid="6" pm="."><plain>Blocking TLR2 activity blunted cardiac dysfunction by 13% and inhibited <z:mp ids='MP_0003141'>cardiac fibrosis</z:mp>, which was associated with a significant suppression of myocardial <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>The underlying mechanism involved interrupting the interaction of TLR2 with its endogenous ligands, resulting in attenuation of <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, blocking TLR4 exacerbated cardiac dysfunction and <z:mp ids='MP_0003045'>fibrosis</z:mp> by amplifying <z:mp ids='MP_0001845'>inflammation</z:mp> and suppressing autophagy </plain></SENT>
<SENT sid="9" pm="."><plain>Our studies demonstrate that TLR2 and TLR4 play distinct roles in the progression of <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>-induced <z:chebi fb="20" ids="15767">DCM</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>TLR4 activity is crucial for the resolution of <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mp ids='MP_0003141'>cardiac fibrosis</z:mp>, while blocking TLR2 activity has therapeutic potential for the treatment of <z:chebi fb="20" ids="15767">DCM</z:chebi> </plain></SENT>
</text></document>